2012-10-10 01:24:11 -
New Pharmaceuticals market report from Global Markets Direct: "AmpliMed Corporation - Product Pipeline Review - 2012"
Global Market Direct's pharmaceuticals report, "AmpliMed Corporation - Product Pipeline Review - 2012" provides data on the AmpliMed Corporation's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, AmpliMed Corporation's corporate website, SEC filings, investor presentations and featured press releases, both from AmpliMed Corporation and industry-specific third party sources, put together by Global Markets Direct's team.
Full Report Details at
- www.fastmr.com/prod/468658_amplimed_corporation_product_pipeline ..
Scope
* AmpliMed Corporation - Brief AmpliMed Corporation overview including business description, key information and
facts, and its locations and subsidiaries.
* Review of current pipeline of AmpliMed Corporation human therapeutic division.
* Overview of pipeline therapeutics across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of AmpliMed Corporation with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the AmpliMed Corporation's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.
Reasons to buy
* Evaluate AmpliMed Corporation's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of AmpliMed Corporation in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the AmpliMed Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with AmpliMed Corporation.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of AmpliMed Corporation and identify potential opportunities in those areas.
Report Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
AmpliMed Corporation Snapshot
AmpliMed Corporation Overview
Key Information
Key Facts
AmpliMed Corporation - Research and Development Overview
Key Therapeutic Areas
AmpliMed Corporation - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
AmpliMed Corporation - Pipeline Products Glance
AmpliMed Corporation - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
AmpliMed Corporation - Drug Profiles
AMP-500
Product Description
Mechanism of Action
R&D Progress
AMP-507
Product Description
Mechanism of Action
R&D Progress
Amplizone
Product Description
Mechanism of Action
R&D Progress
AmpliMed Corporation - Pipeline Analysis
AmpliMed Corporation - Pipeline Products by Therapeutic Class
AmpliMed Corporation - Pipeline Products By Mechanism of Action
AmpliMed Corporation - Dormant Projects
AmpliMed Corporation - Locations And Subsidiaries
Head Office
Financial Deals Landscape
AmpliMed Corporation, Deals Summary
AmpliMed Corporation, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
AmpliMed Secures $3.8 Million In Series D Financing
AmpliMed Secures $5.1 Million In Series C Financing
AmpliMed Secures Additional $8.5 Million In Series B Financing
Licensing Agreements
AmpliMed Enters Into Licensing Agreement With HANDOK Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
AmpliMed Corporation, Key Information
AmpliMed Corporation, Key Facts
AmpliMed Corporation - Pipeline by Indication, 2012
AmpliMed Corporation - Pipeline by Stage of Development, 2012
AmpliMed Corporation - Monotherapy Products in Pipeline, 2012
AmpliMed Corporation - Pre-Clinical, 2012
AmpliMed Corporation - Pipeline By Therapeutic Class, 2012
AmpliMed Corporation - Pipeline Products By Mechanism of Action, 2012
AmpliMed Corporation - Dormant Developmental Projects,2012
AmpliMed Corporation, Deals Summary
AmpliMed Secures $3.8 Million In Series D Financing
AmpliMed Secures $5.1 Million In Series C Financing
AmpliMed Secures Additional $8.5 Million In Series B Financing
AmpliMed Enters Into Licensing Agreement With HANDOK Pharma
List of Figures
AmpliMed Corporation - Pipeline by Indication, 2012
AmpliMed Corporation - Pipeline by Stage of Development, 2012
AmpliMed Corporation - Monotherapy Products in Pipeline, 2012
AmpliMed Corporation - Pipeline Products By Mechanism of Action, 2012
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at
www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at
www.fastmr.com or call us at 1.800.844.8156.
